Angelina Jolie's case highlights the importance of knowing …
A group of more than 120 cancer researchers and physicians took…
Three scientists at universities in Pennsylvania, Illinois and …
Advertisement
Pfizer says Torisel-Avastin failed in cancer study
No difference in disease progression
Updated: Friday, 10 Aug 2012, 4:37 PM EDT
Published : Friday, 10 Aug 2012, 4:37 PM EDT
NEW YORK (AP) - Pfizer said Friday that its drug Torisel failed to help patients with a form of advanced kidney cancer when combined with Roche's drug Avastin.
The study compared renal cell carcinoma patients taking the Torisel-Avastin combination to those taking Avastin plus another cancer drug.
Patients taking the Pfizer combination did not show slower disease progression than those in the other group. Pfizer said.
Torisel is already approved as a stand-alone treatment for advanced renal cell carcinoma.
Email This
Print This
View Story on a Single PageAdvertisement
Advertisement
Advertisement
More on WISHTV.com
-
Here's some dramatic video of the massive tornado that ravaged Moore, Okla., on Monday.
-
JERSEY CITY, N.J. (AP) — A goat believed to have escaped en route to a slaughterhouse …
-
WASHINGTON (AP) — A Massachusetts congressman says investigators still don't know whether…
-
Learn more about the people who appear on air at 24-Hour News 8.
-
PARIS (AP) — Police say an expensive necklace was stolen overnight in the luxurious …
-
A tornado roared through Oklahoma City suburbs, flattening entire neighborhoods, setting …
-
In today's Unique Home Solution Tracy shows you have snapping a picture can be a sure …
